Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04254835
Other study ID # 221091
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date February 1, 2020
Est. completion date August 1, 2020

Study information

Verified date February 2020
Source Cairo University
Contact Hadeer H Mohamed
Phone 01015779373
Email hadeer.hesham91@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Two different Fluoride varnish systems(Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride (CPC) and conventional fluoride) will be applied to high caries risk patients to assess their clinical effects on plaque accumulation and plaque bacterial count .


Description:

Preoperative steps:

- The diagnostic chart will be filled including all data about the patient's medical history, dental history, plaque assessment and plaque bacterial count.

- Scaling and polishing will be carried out for subjects.

clinical steps:

- Control Group: Conventional Fluoride varnish (Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein) will be applied on dry teeth in a thin layer, allowed to dry for 1 minute, and participants will be instructed to avoid rinsing after application, only spitting. Eating, drinking and brushing should be avoided for 1 hour after varnish application.

- Intervention Group: Varnish containing Fluoride, Chlorhexidine and Cetylpyridinium Chloride (Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein) will be applied on dry teeth in a thin layer, allowed to dry for 1 minute, and participants will be instructed to avoid rinsing after application, only spitting. Eating, drinking and brushing should be avoided for 1 hour after varnish application.

Each participant will be assessed for plaque retention using plaque index and Standardized photography and image analysis to disclosed dental plaque, and plaque bacterial count using culture media sensitive for mutans streptococci (MS) in the following intervals:

- Enrolment Baseline assessment

- First visit (2nd week)

- Second visit (4th week)

- Third visit (12th week)

- Fourth visit (24th week)


Recruitment information / eligibility

Status Recruiting
Enrollment 34
Est. completion date August 1, 2020
Est. primary completion date July 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

Patients with good general state of health.

- No signs of periodontitis.

- Patients had a recorded high bacterial count after caries risk assessment.

- No antibiotic treatment within 1 month prior to the start of the trial.

- No current medication with anti-inflammatory drugs.

- No use of antiseptic mouth rinses.

- Non-smokers.

Exclusion Criteria:

- Patients with disabilities, systemic disease or severe medical conditions.

- Patients with severe or active periodontal disease.

- Antibiotic treatment within 1 month prior to the start of the trial.

- Current medication with anti-inflammatory drugs.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein
Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein
Conventional Fluoride varnish

Locations

Country Name City State
Egypt Faculty of dentistry Cairo Universty Giza

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Other Plaque bacterial count Culture media for mutans streptococci (MS) is used to measure (MS) count in collected plaque samples Patient will be evaluated at 2nd, 4th, 12th and 24th week of the study in the morning before teeth brushing.
Primary Plaque Retention Checked using a disclosing agent by Silness and Löe Dental Plaque index Patient will be evaluated at 2nd week of the study in the morning before teeth brushing.
Primary Plaque Retention Checked using a disclosing agent by Silness and Löe Dental Plaque index Patient will be evaluated at 4th week of the study in the morning before teeth brushing.
Primary Plaque Retention Checked using a disclosing agent by Silness and Löe Dental Plaque index Patient will be evaluated at 12th week of the study in the morning before teeth brushing.
Primary Plaque Retention Checked using a disclosing agent by Silness and Löe Dental Plaque index Patient will be evaluated at 24th week of the study in the morning before teeth brushing.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03773094 - Antibacterial Effect of Guava Leaves Extract Mouthwash Compared to Chlorhexidine Mouthwash in High Caries Risk Patients Phase 2/Phase 3
Completed NCT04566120 - Streptococcus Mutans Cariogenicity by Real-time PCR in High Caries Risk Patients N/A
Completed NCT05744622 - Clinical Evaluation of Chemically Cured Conventional Glass Ionomer After Light Emitting Diode Radiant Heat Enhancement N/A
Completed NCT03684993 - Caries Prevention and Side Effects of Gum Arabic and Licorice Extracts Versus Chlorhexidine in High Caries Risk Patients Phase 2/Phase 3